HORSHOLM, Denmark, Sept. 8, 2011 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), formerly LifeCycle Pharma, today announced that John Weinberg, M.D., senior vice president, commercial operations & investor relations of Veloxis, will present at the Rodman & Renshaw Annual Global Investment Conference at 9:35 a.m. EDT, Monday, Sept. 12, at The Waldorf=Astoria in New York. Dr. Weinberg will provide an overview of the company and discuss top-line Phase 3 results of LCP-Tacro™, Veloxis' candidate to prevent organ transplant rejection.
About Veloxis Pharmaceuticals A/S
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Clinical development is the core of Veloxis' efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. Veloxis adapts new technologies on a fast commercial timetable. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability -- at low-scale up costs -- not only for a broad spectrum of drugs already on the market but also for new chemical entities. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
For U.S. investor and media contacts:
John Weinberg, M.D., Senior VP, Commercial Operations and Investor Relations
Veloxis Pharmaceuticals A/S